Research programme: ion channel modulators - Autifony Therapeutics/Boehringer Ingelheim
Latest Information Update: 28 Apr 2025
At a glance
- Originator Autifony Therapeutics; Boehringer Ingelheim
- Class Antidementias; Antiparkinsonians
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
- No development reported Lysosomal storage diseases; Parkinson's disease
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for research development in Lysosomal storage diseases in Germany
- 28 Apr 2025 No recent reports of development identified for research development in Lysosomal storage diseases in United Kingdom
- 28 Apr 2025 No recent reports of development identified for research development in Parkinson's-disease in Germany